RxDoctor Payments Data

Seth Howell, MD

Dermatology · Columbia, SCNPI 1225532369

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,728 of the $53,407 with a category attached, or 85.6%. UCB, Inc. accounts for 95.2% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $51,392, more than ten times the $111 reported in 2022. Among dermatology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,407in general payments, 2019–2025

Across 276 payments — averaging $193.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$51K
  • AbbVie$571
  • Amgen$451
  • Regeneron Healthcare Solutions, Inc.$376
  • Sun Pharmaceutical Industries Inc.$232
  • Lilly USA, LLC$208
  • plus $705 from 10 others

What the payments were for

  • Speaking & faculty fees$45,72886%
  • Travel & lodging$2,9886%
  • Food & beverage$4,6819%
  • Education$100%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,407 in reported general payments places this provider in the 90th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$686,702
Medicare patients
2,258
Services billed
12,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$389,105
Bimzelx AutoinjectorBimekizumab-Bkzx26$383,928
Cosentyx Sensoready (2 Pens)Secukinumab18$132,101
Dupixent PenDupilumab25$94,650
HumiraAdalimumab12$90,307
Clobetasol Propionate256$8,874
Fluorouracil124$7,715
Metronidazole87$4,847
Triamcinolone Acetonide260$3,572
Doxycycline Hyclate90$2,337
Hydrocortisone101$1,727
Desonide43$1,617
Tretinoin30$1,533
Tacrolimus14$1,497
Clindamycin Phosphate43$1,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$571$90,30712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →